UNSPSC 51401532: Iclazepam

This classification denotes a benzodiazepine with the molecular formula C21H21ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FL061Q6NMC, chemically known as 7-chloro-1-(2-(cyclopropylmethoxy)ethyl)-1,3-dihydro-5-phenyl-2h-1,4-benzodiazepin-2-one but generally known as iclazepam, which bears US NIH Compound Identifier 68777. European Medicines Agency schedules Iclazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08105MIG.

UNSPSC 51401532 Iclazepam, a Commodity code, nominally addresses a specific pharmaceutical product, but state and local governments soliciting under this code are actually buying a much broader range of pharmaceutical and health-supply products — naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products — through competitive and cooperative purchasing processes. The issuing bodies span county health departments, state health and human services commissions, and multistate cooperative purchasing alliances; Seminole County, Florida and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) appear in recent activity. The scope of work includes annual supply contracts with quarterly or ongoing deliveries, compliance with cGMP and Drug Supply Chain Security Act standards, insurance and E-Verify requirements, and pricing models ranging from fixed-fee to net pricing and WAC-minus structures. Vendors typically must maintain relationships with authorized wholesalers and meet specific product information and electronic data interchange standards.

Recent activity concentrates in Florida and Minnesota, with the Texas Health and Human Services Commission conducting exploratory market research on direct-to-manufacturer prescription programs. Representative recent solicitations include Seminole County's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; MMCAP's S1070000015802 RFP (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities with award effective July 1, 2026; and the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026, due April 3, 2026) exploring vendor capabilities for direct-to-manufacturer prescription initiatives. The MMCAP contract involves a 3 percent administrative fee and two-year initial terms with optional extensions through June 30, 2028.